oncnursingnews1d
How to Overcome 4 Common Barriers to Cancer Clinical Trial Access
An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and ...
oncnursingnews3d
Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer
The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.
oncnursingnews4d
Kathryn Ciccolini
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews4d
Letter Warns Clinicians of Severe Infections With Pralsetinib for NSCLC
An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...
oncnursingnews5d
Barbara A. Leone, RN, BSN, CCM
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews5d
Kathryn Canavan
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews5d
Cilta-Cel May Outperform Standard Care for Relapsed, Refractory Myeloma
An indirect comparison found that cilta-cel may be better than standard of care for patients with lenalidomise-refractory relapsed/refractory myeloma. Ciltacabtagene autoleucel (cilta-cel; Carvykti) ...
oncnursingnews6d
Jennifer L. Redmond, DrPH
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews6d
Mabel Ryder, MD
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews7d
Bobbie J. Rimel, MD
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...